Telomir Pharmaceuticals, Inc. (TELO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $1.08. The rating moved from Neutral to Oversold on August 7, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$1.08
• Last changeMoved from Neutral to Oversold on August 7, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Telomir Pharmaceuticals, Inc. is a micro‑cap biotech with limited public disclosures and correspondingly high uncertainty around financial runway and product prospects. Sector conditions (strong demand for biologics/CDMO services and active partnership/M&A markets) create potential catalysts, but the company is exposed to typical small‑cap biotech risks: dilution, binary clinical/regulatory outcomes, competitive pressures, and low liquidity. Near‑term movement will likely be driven by any corporate updates, financing activity, or industry news; absent clear, company‑specific catalysts the equity should be viewed as speculative with substantial downside risk.

Key factors

• Very limited publicly available financial and operational disclosure, increasing uncertainty around near-term cash runway and revenue prospects
• Micro‑cap biotech profile with high volatility and low liquidity; share price sensitive to binary clinical or partnership news
• Sector tailwinds for biologics, CDMO/CRO demand and diagnostics could provide an addressable market or partnership interest if technology/platform aligns
• Macro environment currently modestly risk‑on and growth‑oriented, which can support small biotech share appreciation in the near term
• Potential upside from clinical readouts, licensing deals, or strategic partnerships given industry's active M&A and collaboration activity

Risks

• Material risk of dilution if cash runway is short and financing is required (equity raises common for companies at this stage)
• Binary clinical or regulatory outcomes that can sharply reduce enterprise value if negative
• Intense competition from established biotech/pharma and emerging therapeutics in similar indications
• Low trading liquidity and wide bid/ask spreads, increasing execution risk for investors
• Unclear commercialization pathway and reimbursement exposure if eventual therapeutics require payer coverage

Latest MarketMoodz coverage

• Telomir-Zn Wins FDA IND Clearance to Start TNBC Trials2026-04-30

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.